troglitazone has been researched along with Thyroid Cancer, Anaplastic in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cotreatment with troglitazone and lovastatin altered the epithelial-to-mesenchymal-transition (EMT) -related marker gene expression of the cells; specifically, E-cadherin expression increased and vimentin expression decreased." | 1.42 | Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells. ( Chin, LH; Hsu, SP; Liang, YC; Zhong, WB, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhong, WB | 2 |
| Tsai, YC | 1 |
| Chin, LH | 2 |
| Tseng, JH | 1 |
| Tang, LW | 1 |
| Horng, S | 1 |
| Fan, YC | 1 |
| Hsu, SP | 2 |
| Liang, YC | 1 |
2 other studies available for troglitazone and Thyroid Cancer, Anaplastic
| Article | Year |
|---|---|
A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Line, Tumor; C | 2018 |
Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells.
Topics: Cell Line, Tumor; Cell Movement; Chromans; Cyclic AMP Response Element-Binding Protein; Cysteine-Ric | 2015 |